EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer ( STARGATE )

Min-Hee Ryu iD, Kyung Hee Lee, Lin Shen iD, Kun-Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik-Joo Chung und 5 weitere

Cancer Medicine · 2023-04 · 12 (7) · 7784-7794

DOI: 10.1002/cam4.5536 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, online erschienen am 14.12.2022. Verfasst von Min-Hee Ryu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. Patients and Methods Patients with metastatic gastric or gastroesophageal junction adenocarcinoma were randomized (1:1) to receive either sorafenib plus XP (S + XP) or XP alone. In cases of disease progression in the XP arm, crossover to sorafenib alone was allowed. The primary endpoint was progression‐free survival (PFS). The secondary endpoints included overall survival (OS), response rates, safety profiles, and biomarkers, and the response rates and PFS with secondline sorafenib alone after progression in the XP arm.

Results

Between Jan 2011 and Feb 2013, a total of 195 patients were accrued (97 in the S + XP arm and 98 in the XP alone arm). The overall response rate was 54% with S + XP, and 52% with XP alone ( p = 0.83). With a median follow‐up of 12.6 months (range, 0.1–29.2), the median PFS assessed by independent review was 5.6 months in the S + XP arm and 5.3 months in the XP arm (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.67–1.27, p = 0.61). Overall survival was not different between the two arms (median 11.7 vs. 10.8 months; HR 0.93, 95% CI 0.65–1.31, p = 0.66). Frequencies of grade 3/4 toxicities were similar between the S + XP and XP alone arms, except for neutropenia (21% vs. 37%), anorexia (0% vs. 5%), and hand‐foot skin reaction (7% vs. 1%). Among 51 patients who crossed over to sorafenib alone after disease progression in the XP arm, there was no objective response and their median PFS was 1.3 months (95% CI, 1.2–1.7).

Conclusion

The addition of sorafenib to XP chemotherapy was safe but not more effective than XP alone for first‐line treatment of metastatic gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansCapecitabineCisplatinSorafenibDisease ProgressionAntineoplastic Combined Chemotherapy ProtocolsTreatment Outcome

Stichwörter der Autor:innen

VEGFcapecitabinechemotherapycisplatingastric cancersorafenib

Substanzen

CapecitabineCisplatinSorafenib

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Department of Hemato-oncology, Yeungnam University Hospital, Daegu, South Korea.
  • Department of Gastrointestinal Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China.
  • Department of Oncology, National Taiwan University Hospital; and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea.
  • Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, South Korea.

ORCID-Profile: Min-Hee Ryu, Lin Shen, Yeul Hong Kim

Förderung

  • Bayer

Zitieren

APA

Ryu, M. H., Lee, K. H., Shen, L., Yeh, K. H., Yoo, C., Hong, Y. S., Park, Y. I., Yang, S. H., Shin, D. B., Zang, D. Y., Kang, W. K., Chung, I. J., Kim, Y. H., Ryoo, B. Y., Nam, B. H., Park, Y. S., & Kang, Y. K. (2023). Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer ( STARGATE ). Cancer Medicine, 12(7), 7784-7794. https://doi.org/10.1002/cam4.5536

Vancouver

Ryu MH, Lee KH, Shen L, Yeh KH, Yoo C, Hong YS, et al. Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer ( STARGATE ). Cancer Medicine. 2023;12(7):7784-7794. doi:10.1002/cam4.5536

BibTeX
@article{Ryu2023,
  author = {Ryu, Min-Hee and Lee, Kyung Hee and Shen, Lin and Yeh, Kun-Huei and Yoo, Changhoon and Hong, Young Seon and Park, Young Iee and Yang, Sung Hyun and Shin, Dong Bok and Zang, Dae Young and Kang, Won Ki and Chung, Ik-Joo and Kim, Yeul Hong and Ryoo, Baek-Yeol and Nam, Byung-Ho and Park, Young Soo and Kang, Yoon-Koo},
  title = {Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer ( STARGATE )},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {7784--7794},
  doi = {10.1002/cam4.5536}
}
Kostenlos starten →